companydata.dkcompanydata.dk

Drug Development Consulting BidCo ApS: Financial statements 2024

CVR: 42287067

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

Drug Development Consulting BidCo ApS (CVR 42287067) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 3,438,000 and a net result of DKK -13,215,000 compared with DKK -9,381,000 the year before. That is an increase of 48.2% compared with the year before. Equity in the 2024 report amounted to DKK 78,983,000. The solvency ratio was 62.7%. The company had 1 employee in the financial year.

Gross Profit
DKK 3,438,000
Profit/Loss
DKK -13,215,000
Equity
DKK 78,983,000
Total Assets
DKK 126,045,000
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024-3.4M-13.2M79M1
2023-2.3M-9.4M70.2M1
2022-3.8M-11.8M71.8M1

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Drug Development Consulting BidCo ApS: The 2023 annual report is outMay 2, 2024

Drug Development Consulting BidCo ApS has published its annual report for 2023. Gross profit came to DKK 2,320,000, and the net result was DKK -9,381,000.

Mette Kirstine Agger leaves the board of Drug Development Consulting BidCo ApSApr 25, 2024

As of April 25, 2024, Mette Kirstine Agger has left the board of directors of Drug Development Consulting BidCo ApS.

About Drug Development Consulting BidCo ApS

Drug Development Consulting BidCo ApS is a Danish company of the type Anpartsselskab based in Brøndby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of René Holmen Pedersen. The board consists of Niels Peder Nielsen (chair), Alejandra Maria Cristina Bonifacini Mørk, Rafael Natanek and Redmar Koene. The company is owned by Drug Development Consulting Holding ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 5,875,000 and a net result of DKK -61,325,000 compared with DKK -13,215,000 the year before. Equity in the 2025 report amounted to DKK 32,493,000.

Source: annual report 2025, Danish Business Authority

Other financial years